Abstract:Purpose Sirtuin7 (SIRT7), as a member of the sirtuin and NAD + -dependent protein-modifying enzyme family, plays an important role in regulating cellular metabolism, stress responses, tumorigenesis, and aging. Ubiquitination and deubiquitination are reversible post-translational modifications that regulate protein stability, enzyme activity, protein–protein interactions, and cellular signaling transduction. However, whether SIRT7 is regulated by deubiquitination signaling is unclear. This study aims to elucidate the molecular mechanism of SIRT7 via deubiquitination signaling. Methods USP17L2 or SIRT7-targeting shRNAs were used to deplete USP17L2 or SIRT7. Western blot was applied to assess the effects of USP17L2 or SIRT7 depletion. A co-immunoprecipitation assay was used to detect the interaction relationship. Cell Counting Kit-8 assays were applied to assess the viability of breast cancer cells. An immunohistochemistry assay was employed to detect the protein level in samples from breast cancer patients, and the TCGA database was applied to analyze the survival rate of breast cancer patients. Statistical analyses were performed with the Student’s t test (two-tailed unpaired) and χ 2 test. Results We find that the deubiquitinase USP17L2 interacts with and deubiquitinates SIRT7, thereby increasing SIRT7 protein stability. In addition, USP17L2 regulates DNA damage repair through SIRT7. Furthermore, SIRT7 polyubiquitination is increased by knocking down of USP17L2, which leads to cancer cells sensitizing to chemotherapy. In breast cancer patient samples, high expression of USP17L2 is correlated with increased levels of SIRT7 protein. In conclusion, our study demonstrates that the USP17L2-SIRT7 axis is the new regulator in DNA damage response and chemo-response, suggesting that USP17L2 may be a prognostic factor and a potential therapeutic target in breast cancer. Conclusion Our results highlighted that USP17L2 regulates the chemoresistance of breast cancer cells in a SIRT7-dependent manner. Moreover, the role of USP17L2 as a potential therapeutic target in breast cancer and a prognostic factor for patients was elucidated.

USP2a Supports Metastasis by Tuning TGF-β Signaling.

USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1

USP1 Inhibition Destabilizes KPNA2 and Suppresses Breast Cancer Metastasis

USP8 promotes cancer progression and extracellular vesicle‐mediated CD8+ T cell exhaustion by deubiquitinating the TGF‐β receptor TβRII

USP2 Promotes Progression in Triple Negative Breast Cancer

Stabilization of IGF2BP1 by USP10 Promotes Breast Cancer Metastasis Via CPT1A in an M6a-Dependent Manner

USP2 promotes cell migration and invasion in triple negative breast cancer cell lines

Deubiquitinating Enzyme USP10 Promotes Hepatocellular Carcinoma Metastasis Through Deubiquitinating and Stabilizing Smad4 Protein

Ubiquitin-specific protease 22 controls melanoma metastasis and vulnerability to ferroptosis through targeting SIRT1/PTEN/PI3K signaling

The deubiquitinase USP2a promotes tumor immunosuppression by stabilizing immune checkpoint B7-H4 in lung adenocarcinoma harboring EGFR-activating mutants

USP33 promotes pancreatic cancer malignant phenotype through the regulation of TGFBR2/TGFβ signaling pathway

USP5 Promotes Metastasis in Non-Small Cell Lung Cancer by Inducing Epithelial-Mesenchymal Transition Via Wnt/β-Catenin Pathway

USP1 Promotes GC Metastasis Via Stabilizing ID2

USP17L2-SIRT7 axis regulates DNA damage repair and chemoresistance in breast cancer cells

Deubiquitinase USP20 promotes breast cancer metastasis by stabilizing SNAI2

Stabilization of PTGES by deubiquitinase USP9X promotes metastatic features of lung cancer via PGE2 signaling

USP4 is Regulated by AKT Phosphorylation and Directly Deubiquitylates TGF-β Type I Receptor

Ubiquitin-specific peptidase 22 controls integrin-dependent cancer cell stemness and metastasis

Stabilization of PTGES by deubiquitinase USP9X promotes metastatic features of lung cancer via PGE 2 signaling.

Dysregulation and oncogenic activities of ubiquitin specific peptidase 2a in the pathogenesis of hepatocellular carcinoma

USP22 Drives Colorectal Cancer Invasion and Metastasis Via Epithelial-Mesenchymal Transition by Activating AP4